These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 9033367)

  • 1. Newer approaches to regional cancer therapy through tumour immunology: is there a 'breakthrough'?
    Stephens FO
    Aust N Z J Surg; 1997 Jan; 67(1):2-4. PubMed ID: 9033367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic or regional chemotherapy: does it matter and should surgeons be involved?
    Stephens FO
    J R Coll Surg Edinb; 1998 Apr; 43(2):80-1. PubMed ID: 9621525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.
    Lejeune FJ; Rüegg C
    Bull Cancer; 2006 Aug; 93(8):E90-100. PubMed ID: 16935777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency of recombinant human TNF in human cancer therapy.
    Lejeune FJ; Liénard D; Matter M; Rüegg C
    Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
    Sorkin P; Abu-Abid S; Lev D; Gutman M; Aderka D; Halpern P; Setton A; Kudlik N; Bar-On J; Rudich V
    Arch Surg; 1995 Oct; 130(10):1079-84. PubMed ID: 7575120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of isolation-perfusion of the limbs in melanomas and sarcomas].
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B
    Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
    Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
    Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management and current research in isolated limb perfusion for sarcoma and melanoma.
    Hohenberger P; Kettelhack C
    Oncology; 1998; 55(2):89-102. PubMed ID: 9499194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan.
    Lindnér P; Fjälling M; Hafström L; Kierulff-Nielsen H; Mattsson J; Scherstén T; Rizell M; Naredi P
    Eur J Surg Oncol; 1999 Apr; 25(2):179-85. PubMed ID: 10218462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curative and palliative aspects of regional chemotherapy in combination with surgery.
    Müller H; Hilger R
    Support Care Cancer; 2003 Jan; 11(1):1-10. PubMed ID: 12527948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models.
    Eggermont AM
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1357-70. PubMed ID: 8854755
    [No Abstract]   [Full Text] [Related]  

  • 12. Induction chemotherapy: to downgrade aggressive cancers to improve curability by surgery and/or radiotherapy.
    Stephens FO
    Eur J Surg Oncol; 2001 Nov; 27(7):672-88. PubMed ID: 11669597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver.
    Alexander HR; Bartlett DL; Libutti SK
    Oncologist; 2000; 5(5):416-24. PubMed ID: 11040278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents.
    ten Hagen TL; Eggermont AM
    Int J Hyperthermia; 2006 May; 22(3):241-6. PubMed ID: 16754345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion.
    van Horssen R; Rens JA; Brunstein F; Guns V; van Gils M; Hagen TL; Eggermont AM
    Int J Cancer; 2006 Sep; 119(6):1481-90. PubMed ID: 16615114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases.
    Pass HI; Mew DJ; Kranda KC; Temeck BK; Donington JS; Rosenberg SA
    Ann Thorac Surg; 1996 Jun; 61(6):1609-17. PubMed ID: 8651757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased shedding of soluble TNF-receptor 1 during hyperthermic TNF-α-based isolated limb perfusion.
    Grabellus F; Podleska LE; Bjerlestam S; Sheu SY; Lendemans S; Schmid KW; Taeger G
    Int J Hyperthermia; 2011; 27(1):33-41. PubMed ID: 21073296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperthermic-antiblastic perfusion in the treatment of tumor of the extremities].
    Di Filippo F; Cavaliere F; Anzà M; Garinei R; Rossi CR; Deraco M; Perri P; Botti C; Cigna E
    Suppl Tumori; 2002; 1(3):S35-7. PubMed ID: 12415785
    [No Abstract]   [Full Text] [Related]  

  • 19. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors.
    Nakamoto T; Inagawa H; Takagi K; Soma G
    Anticancer Res; 2000; 20(6A):4087-96. PubMed ID: 11131677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs.
    Eggimann P; Chioléro R; Chassot PG; Lienard D; Gerain J; Lejeune F
    Chest; 1995 Apr; 107(4):1074-82. PubMed ID: 7705119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.